AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash

AbbVie (ABBV) announced on Monday it would acquire biotech Apogee Therapeutics for $10.9 billion in cash, as the U.S. drugmaker builds its next-generation immunology pipeline, according to Reuters.

Deal Details

• Value: $10.9 billion in cash
• Payment Method: All-cash
• Target: Apogee Therapeutics (biotech company)
• Sector: Immunology

Rationale Behind the Deal

AbbVie aims to strengthen its immunology pipeline through this acquisition, a key focus area for the company. The move is part of AbbVie's strategy to diversify its revenue streams and reduce reliance on Humira, which faces increasing competition.

Regulatory Hurdles

The deal is expected to undergo regulatory approvals, including from the U.S. Federal Trade Commission (FTC) and the European Competition Authority. AbbVie has not yet announced a timeline for closing the deal.

Impact on Stocks

No immediate comment from AbbVie or Apogee Therapeutics regarding the impact on stock prices. However, investors are likely to monitor the deal's progress and its effect on both stocks.